Summary
Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia (CML) can be successfully treated with Glivec (Imatinib), which is available free of cost through the Glivec International Patient Assistance programme (GIPAP) to patients with proven CML without means to pay for the drug. We review the acquired mutations in the tyrosine kinase encoded by the BCR-ABL1 gene underlying Glivec failure or resistance in a cohort of 388 imatinib-treated CML patients (149 Female and 239 male) registered between February 2003 and June 2016 in Nepal. Forty-five patients (11 female 34 male) were studied; 18 different BCR-ABL1 mutations were seen in 33 patients. P-loop mutation, Kinase domain and A-loop mutations were seen in 9, 16 and 4 patients respectively. Other mutations were seen in five patients. A T315I mutation was the most common mutation, followed by F359V and M244V. Sixteen mutations showed intermediate activity to complete resistance to Glivec. Among the 45 patients evaluated for BCR-ABL1 mutations, 4 were lost to follow-up, 14 died and 27 are still alive. Among the surviving patients, 16 are receiving Nilotinib, 5 Dasatinib and 3 Ponatinib, while 3 patients were referred to India, one of who received allogenic bone marrow transplantation. Understanding the spectrum of further acquired mutations in BCR-ABL1 may help to choose more specific targeted tyrosine kinase inhibitors that can be provided by GIPAP.
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Chronic myeloid leukaemia (CML) is characterized by the presence of Philadelphia chromosome (Ph) which results from the t(9;22)(q34;q11) balanced reciprocal translocation. This translocation produces the BCR-ABL1 oncogene, encoding a chimeric BCR-ABL1 protein that constitutively activates the tyrosine kinase (Quintas-Cardama & Cortes, 2006) . The breakpoint within the ABL1 gene takes place either up stream of exon 1b, downstream of exon 1a or, more frequently, between 1b and 1a (Melo, 1996) . The major breakpoint cluster region (M-bcr) spans from exons e12-e16 (formerly called b1-b5). Alternative splicing gives rise to a fusion transcript with either b2a2 or b3a2 junctions that generate at 210-kDa protein (p210 BCR-ABL1 ) (Faderl et al, 1999) . In rare cases of CML, the breakpoint localizes to an area between e2' and e2 (minor break-point cluster region or m-bcr), which generates an e1a2 transcript that translates a p190 BCR-ABL1 protein. In extremely rare conditions, the breakpoint cluster region (lbcr) gives rise to chronic neutrophilic leukaemia (Pane et al, 1996) . The subsequent dysregulation of the ABL1 protein leads to enhanced proliferation, resistance to apoptosis and altered adhesion, which is the hallmark of CML. Imatinib, a tyrosine kinase inhibitor (TKI), has the ability to bind and occupy the inactive conformation of BCR-ABL1 leading to the disruption of ATP binding site, so preventing a conformational change of the protein to the active form and subsequently leading to the death of the target cells (Schindler et al, 2000) . Imatinib, Nilotinib and Dasatinib are TKIs that are approved for use as first-line treatment of CML in chronic phase or, at a higher dose, for treating advanced phase CML (Baccarani et al, 2013) (Table I) .
BCR-ABL1 mutations (Fig 1) impair the binding of Imatinib while conserving the ATP binding or alter the specific protein conformation that is needed for the binding of Imatinib and thus leading to the conformational change of the BCR-ABL1 and subsequent activation of catalytic activity (Cowan-Jacob et al, 2004) . About 20-40% of the patients receiving first-line Imatinib treatment will ultimately require an alternative therapy due to intolerance or the development of resistance to the drug (O'Brien et al, 2003; Druker et al, 2006) . The possible causes of resistance to Imatinib therapy are shown in Fig 2 ( Apperley, 2007) .
Study methods
This is a retrospective analysis of Philadelphia chromosome/ BCR-ABL1 positive CML patients treated at Patan Hospital, Kathmandu, Nepal, who developed resistance to Glivec (Imatinib). Glivec and Tasigna (nilotinib), both from Novartis This study profiles the mutations acquired by CML patients who did not achieve the adequate response to Glivec (Table I) .
Inclusion criteria
All patients diagnosed as CML both at our hospital and those referred from other institutions who had undergone mutational study were included. Mutational study was conducted in those patients with a loss of haematological response, patients showing the warning response or failure in two tests performed at least 3 months apart or the increase of 1 log BCR-ABL1 transcript from the baseline test.
Exclusion criteria
Patients who had achieved the optimal response to Imatinib were excluded. (c) Inter-patient exposure variability due to differences in metabolizing enzyme activity (Schmidli et al, 2005) . (d) Different efflux and uptake transporter activities (Picard et al, 2007) .
(e) Differences in clinical features (Sokal score) at base line (Apperley, 2007) . (f) Any reasons causing a delayed time to complete cytological response (CCyR) (Wilkinson, 1996) . Thirty-four mutations and their site in the BCR/ABLL1 protein are shown in Table II . Eighteen distinct types of mutations were seen in our study (Table II) . A mutation in the P loop of BCR/ABLL1 was seen in 9/33 (27Á3%) patients and the Kinase domain mutation in another 16/33 (48Á5%) patients. An A-loop mutation was found in 4/33 (12Á1%) patients. Other mutations were seen in 5/33 (15Á1%) patients.
The mutations seen in more than one patient were T315I (6/33, 18Á2%), F359V/C (5/33, 15Á2%), M244V (4/33, 12Á1%) followed by G250E, Y253H, E355G, L387M and H396R, which were each found in two patients.
Out of 18 mutation types, 16 had been previously associated with Imatinib resistance. The mutations that have a strong resistance to Imatinib, i.e., T315I, E255V, Y253H, L248V, E279K and G250E, were documented in 13 patients. The mutations that conferred intermediate resistance to Imatinib, i.e., H396R, F359V, F317L, Q252H, L387M, F359C, M351T, M244V, E355G and V379I, were found in 19 patients.
Management

Patients with P loop mutations
Patients with P-loop mutations were given alternative TKIs (Table II) . At the time of this analysis, five patients were alive, two patients were lost to follow up and two patients had died. Both the patients with Y253H initially received Nilotinib and were later switched to Dasatinib; one patient was referred to India for Dasatinib and another patient who received Dasatinib was enrolled in GIPAP scheme. The patient with E255V mutation was also referred to India for Dasatinib. The patient with L248V mutation received Dasatinib from our centre.
Two patients had the G250E mutation, both of whom received Nilotinib. However, one patient was lost to follow-up and the other died. Another patient with the Q252H mutation also received Nilotinib but died. Two patients with E279K and E459K mutations were started on Nilotinib. The former patient was alive and the latter was lost to follow-up.
Kinase domain mutations
Of the patients who had kinase domain mutation, nine patients were alive, four were lost to follow-up and three had died. There were four patients with F359V mutation. Three of these patients received Nilotinib and one patient was on Imatinib. Nilotinib was continued in one patient but the remaining two patients were changed to Dasatinib as they were not responding to Nilotinib. One patient developed the M244V mutation as well as a F359V mutation. One other patient with a F359C mutation was treated with Nilotinib.
Six patients had the T315I mutation. One patient was referred for haematopoietic stem cell transplantation. Three patients were put on Ponatinib and two patients received Omacetaxime. One patient who received Omacetaxime was lost to follow-up and the other died. The patient with M351T was alive and was receiving Nilotinib at the time of this analysis.
There were three patients with V379I and E355G mutations, all of whom continued with Imatinib. Two patients were lost to follow-up and one patient died.
There were three deaths in the patients with the kinase domain mutation. One was a patient with the T315I mutation, as discussed above, and the others were the patients with F317L and E355G mutation. They were receiving Nilotinib and Imatinib, respectively. 
Patients with A-loop mutations
An A-loop mutation was seen in four patients. Two mutations were encountered in each of the patients with L387M and H396R mutations. In one patient with L387M mutation, the dose of Glivec was escalated. However, the desired response was not achieved with escalated Glivec and the patient was switched to Nilotinib, but ultimately died. Another patient with the same mutation was started on Nilotinib but was switched over to Dasatinib. Of the patients with H396R mutations, one received Nilotinib and another one was started on Omacetaxine. The patient on Nilotinib was still alive whereas the one on Omacetaxine died.
Patients with other mutations
The M244V mutation was identified in four patients. Three patients had the isolated M244V mutation whereas this was in addition to a F359V mutation in the remaining patient (see above). In this patient, Nilotinib was changed to Dasatinib and the other two patients were maintained on Nilotinib. However, one patient who was maintained on Imatinib was later lost to follow-up.
The patient with the splice variant mutation was put on Nilotinib but later died.
Patients with no detectable mutations
There were 12 (26Á6%) patients in whom a mutation was not detected. Eleven patients were started on Nilotinib but in one, the dose of Imatinib was escalated but that patient died. One patient on Nilotinib died and another was lost to follow-up. In one patient, Nilotinib was changed to Omacetaxine and that patient later became lost to follow-up. In total, there were two deaths and two patients were lost to follow-up in this group.
Discussion
Our study is the largest study of BCR-ABL1 mutations that occurred in CML patients treated with Imatinib in Lower and Middle Income Countries and demonstrates how patients developing resistance to Imatinib can be managed by alternative TKIs provided by Novartis and distributed by the MAX Foundation under GIPAP.
In our study, BCR-ABL1 mutations were identified in 33 out of 45 patients (73%) who had documented failure to Imatinib at various times, as the presence of mutation is time dependent (Jabbour et al, 2006) . Thirty-four mutations were seen in 33 patients. In the study conducted by Jabbour et al (2006) , mutations were seen in 62 out of 171 (36Á7%) patients and the total number of mutations was 67. In another study by the same authors, reporting 169 patients who failed treatment with Interferon plus Cytarabine and Imatinib, mutations were seen in 86 (50Á9%) patients and total of 94 mutations were detected (Jabbour et al, 2009) . The rate of mutation in our study is higher than in other studies, although the reasons for this are unclear.
Sixteen of the 18 mutation types detected have previously been associated with Imatinib resistance. The mutations that have a strong resistance to Imatinib (T315I, E255V, Y253H, L248V, E279K and G250E) were documented in 13 patients. The mutations that conferred intermediate resistance to Imatinib (H396R, F359V, F317L, Q252H, L387M, F359C , M351T, M244V, E355G, V379I) were seen in 19 patients. However, there are some inconsistencies between the data of O'Hare et al (2007) and other studies as the G250E mutation is said to have intermediate resistance to Imatinib and M351T and L387M mutations were found to be sensitive to Imatinib in the study by O'Hare et al (2007) . The true status of the two mutations, namely E449K and the splice variant, were not known (Jabbour et al, 2010) .
In our study, P-loop mutations were seen in 9/33 (27Á3%), kinase domain mutations were seen in 16/33 (48Á5%) patients, A-loop mutations in 4/33 (12Á1%) patients and other mutations in 5/33 (15Á2%) patients. According to the site of mutation, P-loop mutation is said to have the worst prognosis but the data are conflicting as non P-loop mutation was shown to have worse outcome with poorer survival (Jabbour et al, 2010) . In the study by Jabbour et al (2006) , P-loop mutations were seen in 24/62 (39%) patients with mutations whereas incidence of P-loop mutation is less in our cohort.
The commonest mutations seen in our patients were T315I (n = 6, 18Á2%), F359V/C (n = 5, 15Á2%), M244V (n = 4, 12Á2%) followed by G250E, Y253H, E355G, L387M and H396R, each seen in two patients. However, the most common mutations seen in 94 mutations by Jabbour et al (2009) were G250E (n = 14, 14Á9%), M351T (n = 10, 10Á6%), T315I (n = 9, 9Á6%) and F317L (n = 9, 9Á6%). In another study the most common mutations amongst 67 mutations were G250E (n = 10, 14Á92%), F317L (n = 7, 10Á44%), E355G (n = 7, 10Á44%), M244V n = 6, 8Á95%) (Jabbour et al, 2006 ). Yet another study, which identified 503 mutations in 386 patients, showed 53/503 (10Á6%) patients with T315I, 47/503 (9Á4%) with M351T, 46/503 (9Á2%) with G250E and 35/503 (7%) with F359V (Branford et al, 2009 ). The three most commonly encountered mutations have intermediate resistance to Imatinib. T351I mutation is resistant to all first line TKI and even to Bosutinib (Borrow, 2007; Redaelli et al, 2009; Hiwase et al, 2011) . F359V has intermediate resistance to Nilotinib but is sensitive to Dasatinib. M244V mutation is sensitive to both Nilotinib and Dasatinib (Branford et al, 2009) .
Seven amino acid sites (Table II) are associated with 75% of mutations and 60-66% of patients (Branford et al, 2009 ). In our study, this group of mutations were seen in 19 (57Á6%) patients.
The T315I mutation is highly resistant to Imatinib, Nilotinib and Dasatinib (O'Hare et al, 2007) . This mutation was found in six patients. One patient was referred for bone marrow transplantation, while Ponatinib was started in three patients, who are still alive. Furthermore, Omacetaxine was started on two patients but one patient died and another patient was lost to follow-up. Ponatinib is strictly recommended in patients who have T315I mutation (or who are resistant to or intolerant to other available tyrosine kinase inhibitors) and the survival of 4/6 patients who had the T315I mutation shows the value of testing for BCR-ABL1 mutations.
Y253H, E255V, F359V and Q252H confer intermediate resistance to Nilotinib (O'Hare et al, 2007) . If a patient had one of the first three mutations, they did not achieve complete cytogenetic response at 12 months on Nilotinib (O'Hare et al, 2007) . We reported such mutations in eight patients. Both our patients with the Y253H mutation, which is associated with the highest 50% inhibitory concentration (IC 50 ) for Nilotinib (O'Hare et al, 2007) , were treated with Dasatinib. The patient with E255V mutation was also referred to India for Dasatinib. Out of four patients with F359V mutation, one patient did not receive second line TKI and was lost to follow-up. The other three patients were started on Nilotinib, although two patients were later changed to Dasatinib and one of the patients later developed M244V mutation. One patient was still on Nilotinib at the time of analysis. The patient with Q252H mutation was started on Nilotinib but, unfortunately, the patient died. So, overall two patients were referred for Dasatinib to India, and three patients received Dasatinib from our centre.
Mutations associated with sensitivity to Nilotinib (F317L, L387M, G250E, H396R, M244V, M351T) were seen in 12 patients. Nilotinib was started in nine patients. Two patients were on Imatinib, one of whom had their dose increased but they died; another patient was lost to follow-up. One patient received Omacetaxine but died. Surprisingly, of two patients where Nilotinib was changed to Dasatinib, one died and one was lost to follow-up. Dasatinib was started in patients with L387M mutation and with combined M244V/F359V mutations. Dasatinib was justifiable in the latter patient with double mutation, as F359V mutation is resistant to Nilotinib, but sensitive to Dasatinib. The high frequency of mutations observed reflect the multiple mechanisms and strong selective pressure to develop resistance to TKIs (Borrow, 2007) .
Mutations that have an intermediate resistance to Dasatinib (E255V, F317L, Q252H) were found in three patients (O'Hare et al, 2007) . As described above, the patient with E255V was referred to India for Dasatinib, while the remaining two died while on Nilotinib and Imatinib, respectively.
Dasatinib-sensitive mutations (F359V, L387M, G250E, E355G, Y263H, M244V, H396R, M351T and V379I) (O'Hare et al, 2007) were seen in 20 patients (O'Hare et al, 2007) . Four patients were planned to start on Dasatinib: one patient was referred to India for this treatment, and the other three were treated with Dasatinib at our centre. The two patients with E355G mutation were both on Glivec: one was lost to follow-up and the other patient died. The patient with the variable splice mutation had blast crisis and was started on Nilotinib but died of sepsis.
Overall, mortality was seen in 8/33 patients (24Á2%) and the loss to follow-up is also quite high 6/33 (18Á2%) in the group with mutation. In the patients with the P-loop mutation the mortality and loss to follow-up rates were each 22Á2%. In the patients with the kinase domain mutation the mortality rate was 18Á8% and the loss to follow-up rate was 25%. In the A-loop mutation the mortality rate was 40%. Mortality was seen in two (16Á1%) patients and one patient without documented mutation, but with proven resistance to Glivec, was lost to follow-up. Eleven patients were started on Nilotinib and one patient was switched from Nilotinib to Dasatinib and another patient was switched to Omacetaxine from Nilotinib, but was lost to follow-up. However, Jabbour et al (2006) reported 15% mortality in the patients with documented mutation and 11% in those without mutation. Among the patients with mutation, P-loop mutation had 9% mortality in comparison to 18% in patients with other mutations (Jabbour et al, 2006) . There are four patients who received Omacetaxime as they were not responding to Imatinib. Two patients died and other two were lost to followup. The reason may be that Omacetaxine needs to be administered subcutaneously by injection and, as our patients were from a remote part of the country, the toxicity related with the drug could not be assessed on time and supportive treatment was delayed because they could not come to the hospital on time.
Our study and the treatment protocols that have followed from Imatinib resistance mutation analysis (IRMA) have inevitable limitations. IRMA was not easily available until June 2010. Furthermore, there were patients with suboptimal responses for whom IRMA could not be performed due to financial constraints, as it was very expensive for our patients. Among the patients who did not undergo IRMA, 11 patients died and 8 of these died within 8 months of treatment due to disease progression. It is probable that these patients had primary resistance and possible that use of IRMA would have allowed a switch to more alternative, effective TKIs. Nine patients were lost to follow-up, none of whom had IRMA performed. Five other patients were started on Nilotinib without IRMA as they were found to have evidence of resistance and/or haematological failure. Two of these patients died due to disease progression within a few days of starting Nilotinib. The remaining patients who could not afford IRMA were treated with Imatinib dose escalation because second generation TKIs were not available for compassionate use at that time.
In conclusion, Imatinib has become a standard first-line treatment as a targeted therapy in Philadelphia chromosome/ BCR-ABL1 positive CML and has transformed progressionfree survival and overall survival. Unfortunately, we have encountered an increasing number of mutations, usually on a clinical and haematological background of Imatinib resistance. Our series of patients shows how mutation analyses are needed for rational therapeutic decision-making, as the targeted treatment is effective in reversing the disease process. About 10% of all our patients with CML who were treated with Inmatinib provided by GIPAP developed evidence of resistance over time and underwent IRMA. IRMA guided us in selecting the optimal second-or third-generation TKI as the best choice for the patient, although it remains true that the mortality rate is higher in CML patients with mutations compared to those patients without evidence of mutation.
